Lexaria Bioscience (LEXX.Q) announced today that dosing has been completed for its HYPER-H21-2 study, the Company’s second human clinical study of 2021. Hypertension, also known as high blood…
hypertension
Lexaria Bioscience (LLX.C) announced today that treatment and dosing in its human clinical study, HYPER-H21-1, have been completed ahead of schedule. “Completing this work in the midst of…